EGFR and myocardial infarction: Consistent with the effect of pharmacological inhibition of ErbB1 utilizing AG1478, treatment with the anti-ErbB1 antibody cetuximab was associated with increased myocardial infarct sizes and significantly elevated serum troponin levels (Fig. 6d–f).